CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to